<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab4">
 <label>Table 15.4</label>
 <caption>
  <p>Investigational therapy for hepatitis C infection</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Direct acting antiviral therapy</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Ns3/4a protease inhibitors</td>
   </tr>
   <tr>
    <td> Boceprevir/Telaprevir</td>
   </tr>
   <tr>
    <td> BI201335</td>
   </tr>
   <tr>
    <td> Danoprevir</td>
   </tr>
   <tr>
    <td> TMC 435</td>
   </tr>
   <tr>
    <td> Asunaprevir</td>
   </tr>
   <tr>
    <td>NS5B polymerase inhibitors</td>
   </tr>
   <tr>
    <td> GS7977</td>
   </tr>
   <tr>
    <td>NS5A inhibitors</td>
   </tr>
   <tr>
    <td> Daclatasvir</td>
   </tr>
   <tr>
    <td>Combinations without peginterferon</td>
   </tr>
   <tr>
    <td>Treatment targeting host encoded factors</td>
   </tr>
   <tr>
    <td>HCV vaccine</td>
   </tr>
   <tr>
    <td>Complementary medicine</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
